AMCP Nexus

Christina Barrington, VP of pharmacy programs at Priority Health, spoke at AMCP Nexus 2021 about the value of managed care, real-world evidence and more.

Cate Lockhart, Pharm.D., Ph.D., spoke at AMCP Nexus about biosimilars, the insulin biosimilar Semglee and the role of PBMs.

The growing ranks of FDA-approved orphan drugs for rare diseases have saved and improved many lives. But the high-priced drugs are also a major cost burden.

Jen Norton spoke at AMCP Nexus about biosimilar trends of 2021 and what to expect in the next 12 months

Barlow spoke at AMCP Nexus about gene and cell therapy and about how payment models need to adjust to account for their high initial cost and their durable — in some cases lifetime — effects.

The tools for formulary management for atopic dermatitis need flexibility to take into account quality-of-life issues and patient access.

Loucks, manager of specialty clinical pharmacy programs and formulary at Kaiser Permanente Washington, discusses metrics that might give healthcare providers an incentive to address healthcare disparities and concrete steps that could be taken to turn the talk about addressing healthcare disparities into a reality.

If the new drug is approved, a Mayo Clinic expert on hypertrophic cardiomyopathy sees the new medication as probably being among the second-line choices for patients who don’t respond to beta blockers and calcium channel blockers.

The first panel discussion of the meeting was a window into the variety of ways that health plans are working to close health disparities.